Fluidigm and IntegraGen Join Forces to Create a Genetic Analysis Service and European Demonstration Lab
News Jan 27, 2010
Fluidigm, the inventor of integrated fluidic circuits (IFCs), has joined with IntegraGen SA, a provider of genetic research testing services, to bring IFC technology to French researchers.
IntegraGen will offer its services to its customers using the Fluidigm BioMark™ System for Genetic Analysis and the Access Array™ sample preparation system for next-generation sequencing. IntegraGen’s lab will also be a demonstration site for researchers investigating Fluidigm’s technology.
Fluidigm instrumentation, combined with its microfluidic-based chips, provide high-performance, high throughput gene expression, genotyping, digital PCR, and sample preparation for next-generation sequencing.
“With this wonderful partnership, researchers will be able to immediately utilize IntegraGen’s premiere services based on Fluidigm technology and enjoy the benefits of integrated fluidic circuits. In addition, Fluidigm will have a demonstration site for our European customers to observe and understand our easy workflow and other unique capabilities of our technology,” said Dominique Remy-Renou, Fluidigm's Vice President of European Sales and Support.
“IntegraGen is proud to be able to provide Fluidigm’s technology to its customers. These tools complete the IntegraGen Services portfolio and put our lab at the cutting edge of genotyping and next generation sequencing capabilities,” said Emmanuel Martin, director of genomic services at IntegraGen.
In treating inflammatory bowel disease (IBD), physicians can have a hard time telling which newly diagnosed patients have a high risk of severe inflammation or what therapies will be most effective. Now researchers report finding an epigenetic signature in patient cells that appears to predict inflammation risk in a serious type of IBD called Crohn’s disease.